丹楂通脉丸辅助治疗痰瘀互结型冠状动脉粥样硬化性心脏病的效果分析  

Effect of Danzhatongmai Pill on Coronary Atherosclerotic Heart Disease with Phlegm and Blood Stasis

作　　者：李彩红 童慧 陈培亮[1] 邹先智 Li Cai-hong;Tong Hui;Chen Pei-liang;Zou Xian-zhi(Department of Traditional Chinese Medicine Classics,Liuyang Traditional Chinese Medicine Hospital,Changsha 410300,China)

机构地区：[1]浏阳市中医医院中医经典科,湖南长沙410300

出　　处：《四川生理科学杂志》2024年第6期1317-1319,共3页Sichuan Journal of Physiological Sciences

摘　　要：目的:分析丹楂通脉丸在痰瘀互结型冠状动脉粥样硬化性心脏病患者辅助治疗方面的疗效。方法:选取2020年4月至2022年12月的60例痰瘀互结型冠状动脉粥样硬化性心脏病患者作为研究对象。随机将患者分为对照组和观察组,每组各30例。对照组患者行常规干预治疗,观察组在对照组的基础上加用丹楂通脉丸。治疗8 w后分析对比两组的心功能状况,包括室间隔厚度、左室后壁舒张末期厚度、左室收缩末期内径、心搏出量、左室舒张末期内径和左室射血分数,中医证候积分以及治疗疗效。结果:治疗后两组的中医证候积分均比治疗前下降(P<0.05),且观察组的中医证候积分显著低于对照组(P<0.05)。治疗后观察组的各项心功能指标明显优于对照组(P<0.05),且观察组的心功能指标显著低于对照组(P<0.05)。治疗后观察组的有效率83.3%明显高于对照组66.7%(P<0.05)。结论:丹楂通脉丸能够改善痰瘀互结型冠状动脉粥样硬化性心脏病患者的临床症状,提高心脏功能,提高治疗效果。Objective:To analyze the efficacy of Danzhatongmai Pill in the adjuvant treatment of coronary atherosclerotic heart disease with phlegm and blood stasis.Methods:From April 2020 to December 2022,60 patients with coronary atherosclerotic heart disease with phlegm and blood stasis were selected as the study subjects.Randomly divide patients into a control group and an observation group,with 30 cases in each group.The control group received routine intervention treatment,while the observation group received Danzhatongmai Pill in addition to the control group.After 8 weeks of treatment,analyze and compare the cardiac function status of the two groups,including ventricular septal thickness,left ventricular posterior wall end diastolic thickness,left ventricular end systolic diameter,stroke volume,left ventricular end diastolic diameter,left ventricular ejection fraction,traditional Chinese medicine syndrome score,and treatment efficacy.Result:After treatment,the TCM syndrome scores of both groups decreased compared to before treatment(P<0.05),and the TCM syndrome scores of the observation group were significantly lower than those of the control group(P<0.05).After treatment,the various cardiac function indicators of the observation group were significantly better than those of the control group(P<0.05),and the cardiac function indicators of the observation group were significantly lower than those of the control group(P<0.05).The effective rate of 83.3%in the observation group after treatment was significantly higher than that of 66.7%in the control group(P<0.05).Conclusion:Danzhatongmai Pill can improve the clinical symptoms of patients with coronary atherosclerotic heart disease of phlegm and blood stasis type,improve the cardiac function,and improve the therapeutic effect.

关 键 词：丹楂通脉丸 痰瘀互结型 冠状动脉动脉粥样硬化 心脏功能指标 

分 类 号：R541.4[医药卫生—心血管疾病]